Business Context and Reporting Period
This Form 8-K Current Report, dated July 19, 2018, is filed by NanoViricides, Inc., a Nevada corporation. The filing serves as an amendment to a report filed on the same date and discloses the entry into material definitive employment agreements and the appointment of new executive leadership.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and corporate governance changes.
Material Changes and Agreements
Appointment of Chief Executive Officer
Dr. Irach Taraporewala was appointed as Chief Executive Officer, effective September 1, 2018. He is also nominated for election to the Board of Directors.
Employment Agreement with Dr. Taraporewala
- Term: Three years.
- Base Salary: $360,000 annually.
- Equity Grant: Options to purchase 300,000 shares of common stock.
- Exercise Price: $0.492 per share (20% above the $0.41 closing bid price on July 19, 2018).
- Vesting: Three equal annual installments commencing on the effective date.
- Performance Bonuses: Eligible for milestone-based awards contingent on employment status at the time of achievement.
- Severance: Six months' salary and benefits if terminated without cause.
Amendment to Dr. Anil Diwan's Agreement
The filing corrects the equity grant details for Dr. Anil Diwan. He was granted 525,000 shares of Series A Convertible Preferred Stock (previously reported as 225,000) in lieu of cash incentives. These shares vest in three equal annual installments on June 30, 2019, 2020, and 2021.
Outlook, Risks, and Management Commentary
The filing provides background on Dr. Taraporewala's experience, including his role as founding CEO of Ohr Pharmaceutical, Inc., where he advanced a drug through Phase II clinical trials. No specific financial guidance, risk factors, or contingencies regarding the company's operational outlook are disclosed in this document.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 300,000 options granted to Dr. Taraporewala and the 525,000 Series A shares granted to Dr. Diwan.
- Confirm the specific performance milestones required for Dr. Taraporewala's bonus awards as detailed in the attached Exhibit 10.2.
- Review the company's cash position to assess its ability to fund the new $360,000 annual salary obligation starting September 1, 2018.
- Check the status of the shareholder election for Dr. Taraporewala's Board nomination at the next annual or special meeting.